The Dry Eye Drug That Ditched Eye Drops Entirely

Why Harrow, Why Now

Harrow isn't stumbling into ophthalmology. The company already sells VEVYE (for dry eye), IHEEZO (an anesthetic for eye procedures), and TRIESENCE (used in eye surgeries). It posted $272 million in revenue in 2025, up 36% year-over-year, and guided for $350 to $365 million in 2026.

Adding TYRVAYA to that roster is like a restaurant with three solid entrées adding a completely different cuisine. It doesn't compete with VEVYE; it complements it. One's an eye drop, the other's a nasal spray. Doctors now have a reason to call on Harrow for two different dry eye solutions instead of one.

The infrastructure argument matters too. Harrow already has sales reps calling on eye doctors, a reimbursement team negotiating with insurers, and a medical affairs group supporting its products. Bolting TYRVAYA onto that existing machine is far cheaper than building from scratch. It's the classic "buy a product, not a platform" playbook.

TYRVAYA's Bumpy Road to This Point

TYRVAYA didn't arrive here in a straight line. Oyster Point Pharma developed it and won FDA approval in October 2021. The commercial launch followed a month later, and early traction looked promising: prescriptions jumped from about 19,000 in Q1 2022 to roughly 30,000 in Q2 2022, with over 7,400 unique eye care professionals writing scripts.

But Oyster Point was eventually acquired by Viatris, the generics giant formed from the Mylan-Upjohn merger. Viatris is a company that makes thousands of products across dozens of therapeutic areas. A niche ophthalmology nasal spray was never going to get the spotlight treatment there. It's the equivalent of a craft brewery getting absorbed by a multinational conglomerate: the beer might be great, but nobody at headquarters is going to obsess over it.

That's where Harrow comes in. For a focused ophthalmology company, TYRVAYA isn't a side project. It's a centerpiece.

The Dry Eye Market Is Massive (and Underserved)

Dry eye disease affects a staggering number of people. In the U.S. alone, roughly 16 million people have been diagnosed, but the actual number could be two to three times higher when you include undiagnosed cases. Globally, estimates range as high as 300 million people affected.

The drivers are everywhere: aging populations, more screen time, environmental factors like air conditioning and pollution. If you've ever spent eight hours staring at a laptop in a climate-controlled office and wondered why your eyes feel like sandpaper, congratulations: you've experienced the market thesis firsthand.

Despite all those patients, current treatments still leave gaps. Many people cycle through artificial tears that provide temporary relief, or they try prescription drops that sting and burn enough to make compliance a challenge. Prescription therapies hold about 42% of the market, but with such high prevalence and low diagnosis rates, there's enormous room for growth.

The Bigger Picture

This deal is a window into a broader trend in ophthalmology: focused acquirers are snapping up differentiated products from bigger companies that can't give them proper attention. Viatris didn't need TYRVAYA. Harrow does.

TYRVAYA is already approved in the U.S., China, and Taiwan, with regulatory applications pending in other markets. That international optionality gives Harrow a growth lever it hasn't had before, assuming it can execute outside its home turf.

The transaction is expected to close in the second half of 2026, pending standard closing conditions. If Harrow integrates it smoothly (always a big "if" in dealmaking), TYRVAYA could become the kind of product that transforms a growing ophthalmology company into a dominant one.

At the very least, it's a bet that millions of dry eye patients would rather sneeze than put drops in their eyes. And honestly? That's a bet most of us would take.

Biotech's IPO Window Just Cracked Wide Open

BlossomHill Therapeutics just pulled off a $150 million upsized IPO in the busiest week for biotech listings all year. With 2026 already blowing past 2025's full-year IPO numbers, the biotech market's comeback is looking very real.